FDA Accepts Praxis’s NDA for Essential Tremor Drug, Sets 2027 Review Deadline

Event summary

  • FDA accepted Praxis’s NDA for ulixacaltamide HCl to treat essential tremor in adults.
  • PDUFA target action date set for January 29, 2027; no advisory committee meeting expected.
  • NDA supported by positive Phase 3 Essential3 trial results, showing statistically significant efficacy and a well-tolerated safety profile.
  • Ulixacaltamide received FDA Breakthrough Therapy Designation in December 2025.

The big picture

Praxis’s NDA acceptance marks a critical step in addressing essential tremor, a condition with limited treatment options. The FDA’s Breakthrough Therapy Designation and positive Phase 3 data suggest a strong regulatory and clinical foundation. Success here could validate Praxis’s precision neuroscience approach and bolster its position in the competitive CNS space.

What we're watching

Regulatory Pathway
Whether the FDA review proceeds without delays or additional data requests.
Commercial Readiness
How Praxis prepares for the potential 2027 launch, including market positioning against existing treatments.
Pipeline Momentum
The pace at which Praxis advances other late-stage programs in its CNS portfolio.

Related topics

Drug Development